San Francisco--A history of prostatitis is apparently linked to the development of prostate cancer, although it is unclear whether this is simply a compelling correlation or a potential etiology, according to the authors of a multicenter study presented at the AUA annual meeting.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.